logo-loader
viewGenprex, Inc.

Genprex appoints new vice president of clinical operations

Jan Stevens will take part in supporting clinical development programs for the company’s immunogene therapy Oncoprex

cancer cells
Stevens boasts nearly 20 years of clinical operations experience in the biopharma industry

The clinical-stage gene therapy company Genprex Inc (NASDAQ:GNPX) on Tuesday announced the appointment of Jan Stevens as its vice president of clinical operations.

In her new post, Stevens will take part in supporting clinical development programs for the company’s immunogene therapy Oncoprex, which is currently being evaluated in clinical studies at the MD Anderson Cancer center for the treatment of non-small cell lung cancer.

Stevens will focus in particular on expanding Genprex’s research and clinical development programs, including the expansion of of Genprex’s Oncoprex and Tarceva combination trial across multiple sites in the US.

Stevens, who will join the company’s office in Cambridge, Massachusetts, has served as a clinical consultant to Genprex since June of 2018.

READ: How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer

“We are pleased that Jan is joining our growing team in Cambridge, and believe that she will bring her broad experience in managing the clinical operations for our Oncoprex program,” said Julien Pham, president and chief operating officer with Genprex.

Ms Stevens boasts nearly 20 years of clinical operations experience in the biopharma industry and has worked at early to late-stage oncology companies. Before joining Genprex, she held senior roles at Berg LLC and Ziopharm Oncology. She was also previously an acute care nurse in the Neurology unit at Massachusetts General Hospital.

Stevens received her RN degree with clinical affiliations from Massachusetts General Hospital, Brigham and Women’s Hospital, and Beth Israel Deaconess Hospital, and holds a Bachelor of Liberal Arts with a concentration in Ethics, cum laude, from Harvard University.

Based in Austin, Texas, Genprex, meanwhile, is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex. Last March, the company went public, raising $6.4 million. The biopharma is using the funds to continue clinical trials and accelerate development programs into additional drug combinations.

Contact Ellen Kelleher at [email protected]

 

Quick facts: Genprex, Inc.

Price: 0.2699 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $5.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex reveals positive preclinical data that shows...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive its collaborators from The University of Texas MD Anderson Cancer Center presented data at the recent American Association of Cancer Research Tumor Immunology and Immunotherapy Meeting in Boston. Varner talked through these important...

3 weeks ago

2 min read